. 7. Lee J Lim DH Kim S . Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial . J
Search Results
Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson, and Yi-Jen Chen
Ronald C. Chen, William U. Shipley, Jason A. Efstathiou, and Anthony L. Zietman
extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study . J Urol 2011 ; 186 : 1261 – 1268 . 23. Gray PJ Fedewa SA Shipley WU . Clinical-pathologic stage
Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter
predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate
Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova
sought to elucidate the role of CRT in 458 patients who underwent curative resection with D2 lymph node dissection. 21 Following surgery, patients were randomized to receive chemotherapy alone (6 cycles of capecitabine + cisplatin [XP]) or chemotherapy
Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi
Adjuvant chemotherapy was also administered in 46 patients (30.1%). A total of 73 patients (47.7%) underwent breast-conserving surgery, and 118 (77.1%) underwent axillary lymph node dissection. The rate of pCR was 29.4% (n=45). Most patients (81
Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou
free cervical flaps for repair. The extent of lymph node dissection was at the surgeon's discretion, mainly based on the patients’ medical histories, clinical palpation, imaging data, and intraoperative exploration. If there were several clinically
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
cancer and suggest that pelvic lymph node dissection can be safely avoided in a significant proportion of early-stage cases. 29 – 40 In a meta-analysis of data from 1112 patients with cervical cancer who underwent SLN biopsy, pooled data generated a
Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
retrospective studies have suggested that it is beneficial. 57 – 59 Two randomized clinical trials from Europe reported that routine lymph node dissection did not improve the outcome of endometrial cancer patients, but lymphadenectomy did identify those with
Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass
cancers, the incidence of lymphedema 2 years after surgery was 37%. 66 In one study of 431 survivors of melanoma who had been treated with complete lymph node dissection and/or wide local excision and axillary or inguinal sentinel lymph node surgery, the
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes
base decisions regarding adjuvant treatment for select patients who do not have medical or technical contraindications to lymph node dissection (see “Lymphadenectomy Controversy,” next column, and “Sentinel Lymph Node Mapping” in the complete version of
